共 50 条
- [41] Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancersJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Chapin, William JosephAgarwal, ParulDiCicco, LisaPalmer, RayleighCenou, NadiaHuang, Alexander Chan ChiKarasic, Thomas Benjamin
- [42] Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/ metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatmentANNALS OF ONCOLOGY, 2023, 34 : S589 - S590Jove, M.Brana, I.Oliva Bernal, M.Hernando Calvo, A.Erasun Lecuona, C.Assaf Pastrana, J. D.Mato-Berciano, A.V. Maliandi, M.Torres-Manjon, S.Moreno, R.Le, C.G. Nuciforo, P.Alemany, R.Capella, G.Blasco, C.Cascallo Piqueras, M.Mesia Nin, R.
- [43] Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohortNATURE COMMUNICATIONS, 2024, 15 (01)Saeed, AnwaarPark, RobinPathak, HarshAl-Bzour, Ayah NedalDai, JunqiangPhadnis, MilindAl-Rajabi, RaedKasi, AnupBaranda, JoaquinaSun, WeijingWilliamson, StephenChiu, Yu-ChiaoOsmanbeyoglu, Hatice UlkuMadan, RashnaAbushukair, HassanMulvaney, KellyGodwin, Andrew K.Saeed, Azhar
- [44] Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatmentANNALS OF ONCOLOGY, 2023, 34 : S589 - S589Jove, M.Brana, I.Oliva Bernal, M.Hernando Calvo, A.Erasun Lecuona, C.Assaf Pastrana, J. D.Mato-Berciano, A.Maliandi, M. V.Torres-Manjon, S.Moreno, R.Le, C.Nuciforo, P. G.Alemany, R.Capella, G.Blasco, C.Cascallo Piqueras, M.Mesia Nin, R.
- [45] DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparibJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Guiu Lahaye, SeverineBalmana Gelpi, JudithGauthier, LudovicBigot, FredericGoncalves, AnthonyFrenel, Jean-SebastienBachelot, ThomasDalenc, FlorenceMailliez, AudreyChakiba, CamilleGenet, DominiqueDohollou, NathalieDesmoulins, IsabelleRe Canon, Jean-LucGuyonneau, ClaraBuisson, AdrienChevalier, Louise-MarieDelaloge, SuzetteFollana, Philippe
- [46] A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC)ANNALS OF ONCOLOGY, 2018, 29Kim, R.Kim, D.Alese, O.Li, D.El-Rayes, B.Shah, N.Schell, M.Zhou, J.Chung, V.
- [47] Phase II trial of hepatic arterial infusion chemotherapy plus bevacizumab and toripalimab for advanced biliary tract cancers: efficacy, safety, and exploratory analysisHEPATOBILIARY SURGERY AND NUTRITION, 2025,Zheng, KanglianFu, ShijieZhu, XuCao, GuangXu, LiangLiu, PengGao, SongXu, HaifengGuo, JianhaiChen, HuiLiu, WeiXu, DaWang, LijunYan, XiaoluanBao, QuanWu, JianhuiWang, KunZhou, JunHao, ChunyiXing, BaocaiShen, LinYang, RenjieWang, Xiaodong
- [48] A phase II study to evaluate the efficacy and safety of combination therapy of durvalumab (MEDI4736) and amrubicin in patients with recurrent small cell lung cancer (SCLC): Aphrodite trial, in progress.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Kato, YukaOhashi, KadoakiKozuki, ToshiyukiKuyama, ShoichiYamaguchi, KakuhiroYokoyama, ToshihideUno, HidekiYoshida, MichihiroHattori, NoboruHotta, KatsuyukiKiura, Katsuyuki
- [49] A phase II study of durvalumab (MEDI4736) in combination with a CSF-1R inhibitor (SNDX-6352) following chemotherapy or radio-embolization for patients with intrahepatic cholangiocarcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Baretti, MarinaDing, YingjunBrancati, MadalenaParkinson, RoseLinden, SheilaHong, KelvinLiddell, RobertZheng, Lei
- [50] NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLCJOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S140 - S141Mok, T.Schmidt, P.Aren, O.Arrieta, O.Gottfried, M.Jazieh, A. R.Ramlau, R.Timcheva, K.Martin, C.McIntosh, S.